Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMSI- Apache Medical Systems -- Ignore unavailable to you. Want to Upgrade?

To: Ellen who wrote (10)	7/19/1998 2:47:00 AM
From: Ellen	Respond to of 33

This really impressed me, as Duke is a renown medical facility: Duke University Medical Center and Health System Implements APACHE III Critical Care Series TM McLean, VA -- March 31, 1998 -- APACHE Medical Systems, Inc. (NASDAQ:AMSI) today announced that Duke University Medical Center and Health System has purchased the APACHE III Critical Care Series as a key component of its system-wide information strategy. "Our partnership with APACHE is extremely important and will us assist us significantly in our mission to deliver the best patient outcomes cost-efficiently within Adult Critical Care Services," said Dr. William Fulkerson, Medical Director for Critical Care Services at Duke. "APACHE allows us to accurately adjust for severity and compare results when examining our outcomes and practice. Combining APACHE with our other accounting and resource tracking tools will help us identify and promote the best practice for our patients." Duke University Medical Center and Health System, staffing 850 beds, is an international leader in patient care, medical education and research. Recently named by US News and World Report as one of the nation's best hospitals (fourth in the country), Duke Medical Center serves as a major referral hospital in the South and Eastern regions of the U.S. The APACHE critical care system will be implemented first in the medical and surgical intensive care units (32 beds). Subsequent implementation will add the neuroscience, cardiothoracic and coronary care units, with APACHE products ultimately supporting patient care in 84 adult intensive care beds. "The APACHE III Critical Care Series is a very powerful tool that will assist Duke Critical Care Services in emphasizing quality patient outcomes and efficient operations. Integrating the Discover+ and Voyager+ modules, through HL7 messaging, within our clinical and financial informatics infrastructure will create a tremendous resource for clinicians and operations personnel across our system," according to Landen Bain, Duke's Chief Information Officer. APACHE Medical Systems, Inc. is the recognized leader in the development of risk-adjustment models, clinical decision support tools and quality improvement programs forthe care of high-risk, high-cost patients. The Company's products and services enable health systems, hospitals and providers to apply an evidence-based approach to achieve clinical performance excellence and compete effectively under managed care. The APACHE III Critical Care Series products provide risk-adjusted hospital and health system performance data, comparison to Best Demonstrated practices and norms, as well as prognostic information at the individual patient level. This information is essential for hospitals to identify priorities for quality improvement, measure the results of these efforts and also assists in daily patient care management. The system includes two main modules. Voyager+ provides retrospective analysis, while the Discover+ module offers concurrent and predictive information in support of day-to-day patient care decisions, including at the bedside. All Critical Care Series products are PC-based within a client-server architecture, and are fully Year 2000 ready. Well known internationally for the APACHE III methodology for critical care, APACHE's programs are today helping providers to better manage the clinical, financial and patient satisfaction outcomes of high-risk, high-cost patients in critical, acute, cardiovascular, HIV/AIDS and sub-acute care. Both APACHE's Critical Care Series and Acute Care Voyager+ products are accepted by the Joint Commission on Accreditation of Healthcare Organizations for reporting under the "ORYX" performance measurement initiative.

To: Ellen who wrote (10)	7/19/1998 2:54:00 AM
From: Ellen	Read Replies (1) \| Respond to of 33

APACHE Medical Systems Announces Multiple New Contracts for APACHE III Critical Care Series TM Products and Services McLean, VA -- February 10, 1998 -- APACHE Medical Systems, Inc. (NASDAQ:AMSI), today announced the signing of four new clients for systems and services from the Company1s APACHE III Critical Care Series product line. These new clients include: Moses H. Cone Health System, Greensboro, North Carolina; St. Mary1s Hospital, Huntington, West Virginia; New Hanover Regional Medical Center, Wilmington, North Carolina; and Palmetto Richland Memorial Hospital in Columbia, South Carolina. The APACHE III Critical Care Series products provide risk-adjusted hospital and health system performance data and comparison to Best Demonstrated Practices and norms. This information is essential for hospitals to identify priorities for quality improvement, measure the results of these efforts, and assist in daily patient care management. The system includes two main modules. Voyager+ provides retrospective analysis, while the Discover+ module offers concurrent and predictive information in support of day-to-day patient care decisions, including at the bedside. All Critical Care Series products are PC-based within a client-server architecture, and are Year 2000 ready. 3These hospitals1 commitment to APACHE demonstrates the growing appeal to both the medical community and hospital administration of our evidence-based solutions for the effective management of high-cost, high-risk patients,ý said James L. Elder, the Company1s Vice President of Sales. 3By using the APACHE Critical Care Series and related APACHE Best Care TM Clinical Performance Improvement Programs, our clients are able to realize - and document - substantial and sustainable cost savings while improving care quality, utilization and patient satisfaction.ý APACHE Medical Systems, Inc. is the recognized leader in the development of risk-adjustment models, clinical decision support tools and quality improvement programs for the care of high-risk, high-cost patients. The Company1s products and services enable health systems, hospitals and providers to apply an evidence-based approach to achieve clinical performance excellence, reduce cost and compete effectively under managed care. Well-known internationally for the APACHE III methodology for critical care, the Company1s programs are today helping providers to better manage the clinical, financial and patient satisfaction outcomes of high-risk, high-cost patients in critical, acute, cardiovascular, HIV/AIDS and sub-acute care. Both APACHE1s Critical Care Series and Acute Care Voyager+ products are accepted by the Joint Commission on Accreditation of Healthcare Organizations for reporting under the 3ORYXý performance measurement initiative.

To: Ellen who wrote (10)	7/19/1998 3:00:00 AM
From: Ellen	Read Replies (1) \| Respond to of 33

One more... There's lots more info at their web site under "What's New". The list is fairly impressive. CDC Extends Cooperative Agreement with APACHE for Longitudinal HIV/AIDS Outpatient Research Study McLean, VA--July 8, 1997-- APACHE Medical Systems, Inc. (NASDAQ:AMSI) announced today that the Centers for Disease Control and Prevention (CDC) has extended their Cooperative Agreement with APACHE's Health Research Network Division (HRN) through 2001. HRN has been performing longitudinal data collection and analysis on HIV/AIDS patients since 1992 through the multicenter HIV Outpatient Study (HOPS) project, and has had a formal Cooperative Agreement with the CDC since 1993. Scott Holmberg, Project Officer of the CDC said, "The CDC is pleased to see this Agreement extended. The data are valuable for anyone interested in tracking the changing HIV/AIDS epidemic, and continue to have a variety of public health implications. Nine scientific abstracts resulting from the HOPS project already have been presented at conferences such as the International Conference on AIDS, the Conference on Retroviruses and Opportunistic Infections, the Infectious Disease Society of America, and the Association of Nurses in AIDS Care, and four papers are in development for peer review. These new publications focus on the changing dynamic of HIV illness, treatments, and outcomes as identified through HRN's analysis of the HOPS database." Diane Aschman, General Manager of HRN stated, "This project has provided invaluable insights into the multiple stages of HIV infection, and the efficacy of available treatments in fighting the disease. We are pleased that the CDC is extending the Cooperative Agreement, and we look forward to continuing to perform epidemiological and outcomes analysis for the CDC." As part of the Agreement, the CDC will continue to fund HRN's HIV Outpatient Study (HOPS). The HOPS project has collected and analyzed a national longitudinal epidemiological database of HIV-infected non-AIDS and AIDS patients which is the most comprehensive of its kind. Members of the HOPS project include nine HIV treatment centers including private practices, university health facilities, and public health clinics. HOPS prospectively tracks patients diverse in their geography, race, gender, HIV risk group, and social and economic class through visits to leading community-based HIV clinicians. To date, the HOPS database contains an average of 22 months of demographic, clinical, cost and outcomes data for each of more than 3,000 HIV/AIDS cases. The database is composed of 59% AIDS patients and 41% HIV-infected non-AIDS patients, and has captured all stages of illness for HIV infected patients. Extension of the Agreement ensures the continuing analysis of the growing HOPS database, enabling more research on the effects of new treatments, changes in opportunistic illnesses and infections, and the course of the disease. More immediately, these data can provide indicators to help minimize HIV patients contracting severe late-stage infections. Used as a resource by managed care organizations, the data also can provide a basis for more effective managed care contracts throughout the course of the disease. The APACHE family of companies combines evidence-based medicine and knowledge-based consulting to deliver tools and processes for clinical, financial, and operational performance improvement across the continuum of care. APACHE's data-driven solutions provide a strategic "blueprint" for performance improvement, helping providers and healthcare organizations to improve variations in practice patterns and reduce clinical costs. APACHE patient management products and services give clients real-time, risk-adjusted clinical and financial information they need to manage care, especially for high-risk, high-cost patients. Health Outcomes Research provides clinical trial design services, research support for product marketing, and disease management programs. National Health Advisors focuses on strategy and management support services to improve the performance of hospitals and integrated delivery systems. Worldwide, over 600 healthcare organizations have used APACHE products and services to measure, monitor, and manage change.